The arrival of the Retatru vial signifies a significant shift in the field to metabolic control . This novel drug combines two distinct mechanisms – agonist of the GLP-1 receptor and blocking of the DPP-4 factor – offering a unique technique for addressing obesity . Early clinical data demonstrate promising results in facilitating considerable